# 3D Biomatrix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/3d-biomatrix

- Industry: Biotechnology
- Headquarters: Ann Arbor, US
- Website: www.3dbiomatrix.com
- Total disclosed funding: $0.7M
- Latest round: Series A (May 30, 2012)
- Investors on record: 2

## About

3D Biomatrix Inc specializes in advanced bioprinting solutions that enhance cellular research and development. Their innovative technology supports scientists in creating precise tissue models for better drug testing and regenerative medicine applications.3D Biomatrix Inc, founded in 2010, is based in Ann Arbor, US. The company focuses on providing bioprinting technology to facilitate tissue engineering and drug discovery. They have undergone four funding rounds, with the most recent deal occurring on July 17, 2013, when they raised USD 0.64 mn from unspecified investors. The total amount raised by the firm is USD 0.64 mn.3D Biomatrix Inc offers a variety of bioprinting solutions designed to enhance cellular research and operational efficiency in the life sciences sector. Their core products include advanced bioprinting systems and bio-inks that enable the creation of tissue models for applications such as drug testing and tissue engineering. The products are primarily marketed to academic institutions, research laboratories, and biotechnology firms globally, with a strong presence in North America and Europe. End users include researchers and scientists focused on innovative biomedical applications.The company's revenue model is based on direct sales of bioprinting systems and consumables, as well as ongoing support contracts. By providing flexible pricing for their product offerings, they cater to a wide range of clients from educational institutions to large biotech firms. Revenue is generated from both equipment sales and service contracts, establishing a consistent income stream that supports their operational needs.3D Biomatrix plans to enhance its product portfolio by introducing new bioprinting systems and bio-inks aimed at expanding applications in tissue engineering by the end of 2024. The company is also targeting expansion into European and Asian markets, aiming to establish a presence in Germany and Japan by mid-2025. The recent funding of USD 0.64 mn will be utilized to support research and development initiatives, enhancing their product offerings and facilitating entrance into new markets.

## Funding rounds

- Series A, May 30, 2012, $0.7M — Ann Arbor SPARK, Michigan Economic Development Corporation

## Investors

- Ann Arbor SPARK (https://capitalatlas.ai/funds/ann-arbor-spark) — Series A
- Michigan Economic Development Corporation — Series A